Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.31 USD | -1.87% | -2.02% | +1.77% |
Apr. 17 | Wedbush Raises Price Target on Ardelyx to $14 From $13, Keeps Outperform Rating | MT |
Apr. 05 | Leerink Partners Initiates Coverage on Ardelyx With Outperform Rating, $14 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.77% | 1.5B | |
-2.26% | 104B | |
+1.41% | 97.42B | |
+0.79% | 22.2B | |
-17.84% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-17.63% | 15.06B | |
+4.55% | 13.98B | |
+32.11% | 11.66B |
- Stock Market
- Equities
- ARDX Stock
- News Ardelyx, Inc.
- Ardelyx Says FDA Granted Appeal for Kidney Disease Drug Candidate Application; Shares Rise Pre-Bell